539 related articles for article (PubMed ID: 23816492)
1. Personalized medicine in Alzheimer's disease and depression.
Souslova T; Marple TC; Spiekerman AM; Mohammad AA
Contemp Clin Trials; 2013 Nov; 36(2):616-23. PubMed ID: 23816492
[TBL] [Abstract][Full Text] [Related]
2. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
Gauthier S; Leuzy A; Racine E; Rosa-Neto P
Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Wallin AK; Blennow K; Andreasen N; Minthon L
Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
[TBL] [Abstract][Full Text] [Related]
5. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
6. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.
Dubois B; Feldman HH; Jacova C; Dekosky ST; Barberger-Gateau P; Cummings J; Delacourte A; Galasko D; Gauthier S; Jicha G; Meguro K; O'brien J; Pasquier F; Robert P; Rossor M; Salloway S; Stern Y; Visser PJ; Scheltens P
Lancet Neurol; 2007 Aug; 6(8):734-46. PubMed ID: 17616482
[TBL] [Abstract][Full Text] [Related]
7. The development of effective biomarkers for Alzheimer's disease: a review.
Henry MS; Passmore AP; Todd S; McGuinness B; Craig D; Johnston JA
Int J Geriatr Psychiatry; 2013 Apr; 28(4):331-40. PubMed ID: 22674539
[TBL] [Abstract][Full Text] [Related]
8. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
9. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
10. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
12. Are specific symptoms of depression predictive of Alzheimer's dementia?
Mossaheb N; Zehetmayer S; Jungwirth S; Weissgram S; Rainer M; Tragl KH; Fischer P
J Clin Psychiatry; 2012 Jul; 73(7):1009-15. PubMed ID: 22687442
[TBL] [Abstract][Full Text] [Related]
13. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
Vanitallie TB
Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
[TBL] [Abstract][Full Text] [Related]
14. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.
Trillo L; Das D; Hsieh W; Medina B; Moghadam S; Lin B; Dang V; Sanchez MM; De Miguel Z; Ashford JW; Salehi A
Neurosci Biobehav Rev; 2013 Sep; 37(8):1363-79. PubMed ID: 23707776
[TBL] [Abstract][Full Text] [Related]
15. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
16. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study.
Dolci GAM; Damanti S; Scortichini V; Galli A; Rossi PD; Abbate C; Arosio B; Mari D; Arighi A; Fumagalli GG; Scarpini E; Inglese S; Marcucci M
Front Med (Lausanne); 2017; 4():203. PubMed ID: 29214153
[TBL] [Abstract][Full Text] [Related]
18. The relationship between cerebrospinal fluid biomarkers and depression in elderly women.
Gudmundsson P; Skoog I; Waern M; Blennow K; Pálsson S; Rosengren L; Gustafson D
Am J Geriatr Psychiatry; 2007 Oct; 15(10):832-8. PubMed ID: 17911361
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type.
Wagner M; Teichner G; Bachman DL
Arch Clin Neuropsychol; 2003 Dec; 18(8):893-903. PubMed ID: 14609583
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
